Award

Preventing Cardiovascular Collapse in Sepsis through Senolytic Therapy

Description: Sepsis is a leading cause of death and disability in hospitalized and critically ill patients. Progression to septic shock is a life threatening cardiovascular emergency marked by profound hypotension, circulatory failure, and rapid multiorgan dysfunction. Older adults are especially vulnerable, with higher mortality, long term disability, and reduced quality of life. Despite advances in critical care, reversal of established shock is difficult, underscoring the urgent need for therapies that prevent the transition from infection to cardiovascular collapse. A promising approach targets senescent cells, aged dysfunctional cells that accumulate with age and fuel chronic inflammation. These cells release harmful signals that intensify the immune response during infection, creating a cycle of inflammation that damages vital organs including the heart. Senolytic agents such as fisetin, a natural compound found in strawberries and apples, selectively clear senescent cells. Preclinical studies show fisetin reduces inflammation and improves survival in sepsis models, but its optimal dose, biologic effects, and clinical efficacy in humans are unknown. This project will test fisetin as a senolytic therapy to prevent progression from infection to septic shock and organ failure in older adults. We will participate as a site in the parent trial STOP Sepsis, which is a multicenter, adaptive, randomized, placebo controlled trial with three aims: (1) define the optimal dose of fisetin to reduce senescent cell burden; (2) evaluate its effects on inflammatory pathways linked to cardiovascular collapse; and (3) measure its impact on organ dysfunction, recovery, and patient outcomes, using validated measures and Bayesian methods to estimate the probability of success in a Phase 3 trial. Beyond testing a therapy, this project is grounded in implementation science and health equity. Sepsis disproportionately affects minority and underserved groups, yet they remain underrepresented in trials. Our design emphasizes inclusive enrollment, community engagement, and strategies to lower barriers, ensuring findings are generalizable and translatable to real world care. This work can transform cardiovascular critical care. By targeting aging biology in a high risk population, this study seeks to reduce mortality, improve recovery, and create therapies that halt sepsis before it advances to cardiovascular collapse.
Amount: $343,800
Funding type: research
Funder scheme: Clinical Investigator Leadership Awards - Cardiovascular
Start date: 2026-01-01
End date: 2028-12-31
Field: Medicine
Funded outputs count: 0
Funder award ID: 26CILACV1551188
OpenAlex ID: G3182122467